Crossmark

Venetoclax combined with hypomethylating agents or low-dose cytarabine as induction chemotherapy for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review and meta-analysis

Crossref DOI link: https://doi.org/10.1007/s10238-021-00784-y

Published Online: 2022-01-23

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Qin, Yao

Kuang, Pu https://orcid.org/0000-0002-1007-6784
Liu, Ting
License Information

Text and Data Mining valid from 2022-01-23

Version of Record valid from 2022-01-23
More Information

Article History

Received: 15 May 2021

Accepted: 10 December 2021

First Online: 23 January 2022

Declarations

:

: The authors have no conflicts of interest to declare that they are relevant to the content of this article.

: This review article does not have direct or indirect involvement of humans or animals, so permission from the IRB or ethics committee was not applicable or required.

: It is not necessary to obtain consent because of the already available data.

Document is current

Any future updates will be listed below